Compare SNGX & OLB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNGX | OLB |
|---|---|---|
| Founded | 1987 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6M | 6.6M |
| IPO Year | 2006 | 2019 |
| Metric | SNGX | OLB |
|---|---|---|
| Price | $0.39 | $0.37 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 903.1K | 146.4K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 57.03 | ★ 71.48 |
| EPS | N/A | ★ N/A |
| Revenue | $119,371.00 | ★ $8,676,907.00 |
| Revenue This Year | N/A | $12.19 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.28 | $0.31 |
| 52 Week High | $6.23 | $1.86 |
| Indicator | SNGX | OLB |
|---|---|---|
| Relative Strength Index (RSI) | 39.82 | 31.60 |
| Support Level | $0.37 | $0.31 |
| Resistance Level | $0.41 | $0.59 |
| Average True Range (ATR) | 0.02 | 0.03 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 21.25 | 5.78 |
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).
The OLB Group Inc is a diversified FinTech company that focuses on a suite of products in the merchant services marketplace and seeks to provide integrated business solutions to merchants throughout the United States. The company seeks to provide merchants with a wide range-of-products and services through the various online platforms, including financial and transaction processing services. It also has products that provide support for crowdfunding and other capital-raising initiatives. It supplements the online platforms with certain hardware solutions that are integrated with the online platforms. The company has two business segments: Fintech Services, which generates key revenue, and the Bitcoin Mining business segment.